Abstract:Background: Rituximab is a central component of chemoimmunotherapy for B cell lymphomas. With over two decades in clinical use, new insights into its mechanisms of action continue to emerge. Rituximab infusion into patients results in elevated levels of TNFα in patient sera. However, our understanding of the mechanism of TNFα production in the context of rituximab and its role in anti-tumor immunity remain limited. In our study, we sought to determine the major producers of TNFα following rituximab treatment and the effect of rituximab-induced TNFα on anti-tumor effector cells. Methods: Peripheral blood mononuclear cells (PBMCs) from normal donors were cocultured in vitro with CD20-expressing Raji cells for 1 to 7 days. The coculture was treated with rituximab or non-specific antibody trastuzumab. Recombinant TNFα or TNFα blocking antibody infliximab were used to test the effect of TNFα in the rituximab- or trastuzumab-treated coculture system. ELISA was used to evaluate TNFα production in culture supernatant. Multicolor flow cytometry was used to evaluate for phenotypic and functional changes with TNFα treatment or blockade in various immune cell populations. Results: TNFα was robustly produced by PBMCs when treated with rituximab. This production was mediated by the Fc portion of rituximab antibody, as rituximab Fab elicited very little if any TNFα response from PBMCs. Myeloid dendritic cells (HLA-DR+CD123-CD11c+) were the key producers of TNFα in response to rituximab. In the absence of antibody therapy, recombinant TNFα treatment induced proliferation and survival of two major effector cells in the peripheral blood: monocytes and NK cells as determined by cell count and percent of Ki67+ cells. TNFα blockade using infliximab inhibited monocyte and NK cell proliferation and survival. TNFα blockade also protected Raji cells from rituximab-mediated killing. Conclusions: Rituximab-induced TNFα production promotes the proliferation and survival of monocytes and NK cells. Myeloid dendritic cells are necessary for TNFα production in this context. These results highlight the complexity of the immune response to rituximab treatment. Additional studies are ongoing exploring the role TNFa plays in the therapeutic response to rituximab. Citation Format: Nanmeng Yu, George J. Weiner. TNFα production by myeloid DCs in response to rituximab induces monocyte and NK cell proliferation and survival [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5596.

TNFR1 links TNF exocytosis to TNF production in allergen-activated RBL-2H3 cells

Protein Tyrosine Kinase Fyn Regulates TLR4-Elicited Responses on Mast Cells Controlling the Function of a PP2A-PKCα/β Signaling Node Leading to TNF Secretion

Common and distinct signalling cascades in the production of tumour necrosis factor-alpha and interleukin-13 induced by lipopolysaccharide in RBL-2H3 cells

Allergic Lung Inflammation is Mediated by Soluble Tumor Necrosis Factor (TNF) and Attenuated by Dominant-Negative TNF Biologics

TNF-α augments RANKL-dependent intestinal M cell differentiation in enteroid cultures

TNFR 2 Stimulation Promotes Mitochondrial Fusion Via Stat 3-and NF-kB – Dependent Activation of OPA 1 Expression

TRAF6 Specifically Contributes to FcϵRI-mediated Cytokine Production but Not Mast Cell Degranulation

Regulation of Tumor Necrosis Factor Receptors on Phagocytes

Tnf-Tnfr2 Signaling Inhibits Th2 And Th17 Polarization And Alleviates Allergic Airway Inflammation

The crosstalk between neuropilin-1 and tumor necrosis factor-α in endothelial cells

Modulation of the protein expression of TLR2 by TNF-α in primary rat renal proximal tubule cells

TNF-α Regulates Mast Cell Functions by Inhibiting Cell Degranulation

Abstract 5596: TNFα production by myeloid DCs in response to rituximab induces monocyte and NK cell proliferation and survival

TNF Activates an IRF1-dependent Autocrine Loop Leading to Sustained Expression of Chemokines and STAT1-dependent Type I Interferon–response Genes

TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors

Differential Role of TNF Receptors in Cellular Trafficking of Intact TNF.

Protective role of tumor necrosis factor (TNF) receptors in chronic intestinal inflammation: TNFR1 ablation boosts systemic inflammatory response

The TNF-Family Ligand TL1A and Its Receptor DR3 Promote T Cell–Mediated Allergic Immunopathology by Enhancing Differentiation and Pathogenicity of IL-9–Producing T Cells

Cell-specific expression and lipopolysaccharide-induced regulation of tumor necrosis factor alpha (TNFalpha) and TNF receptors in rat dorsal root ganglion

TANK Potentiates Tumor Necrosis Factor Receptor-Associated Factor-Mediated C-Jun N-terminal Kinase/stress-Activated Protein Kinase Activation Through the Germinal Center Kinase Pathway.

Ephrinb1 Is Essential In T-Cell-T-Cell Co-Operation During T-Cell Activation